Axio BioPharma is revolutionizing biopharmaceutical manufacturing by leveraging AI to accelerate the development of recombinant protein therapeutics, with an initial focus on monoclonal antibodies (mAbs). Our innovative approach significantly shortens the timeline from lab research to clinical readiness, increasing efficiency and reducing costs. Axio is committed to setting new standards in the biopharma industry and advancing therapeutic innovations